in Silico and in Vitro Evaluation of A Recombinant Fusion Peptide as A Novel Candidate Vaccine for EGFR-Positive Tumors
Majid Asadi-Ghalehni1, Mohamad Javad Rasaee2, Masoud Javanmardi2, SaeedKhalili2, MohsenMohamadi1, Farnaz Fatemi1 and Esmaeil Sadroddiny*1
1Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran 2Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, I.R. Iran
DOI : http://dx.doi.org/10.13005/bbra/1917
ABSTRACT: The epidermal growth factor receptor (EGFR) belongs to the ErbB family of receptor tyrosine kinases (RTK). EGFR over expressed in different cancers like neck, lung and breast. Various approaches have been used to activate the immune system against EGFR+ cancer such as vaccine therapy. Herein a recombinant fusion peptide composed of EGFR mimotope and L2 domain of EGFR designed. Using in silico studies the potency of the peptide as a vaccine evaluated. This peptide was then cloned into an expression vector and expressed in E. Coli. The ELISA results of the purified peptide against anti EGFR antibodies showed that this peptide could be functional as a vaccine candidate against EGFR-positive tumors.
KEYWORDS: epidermal; receptor; kinases; Evaluation
Download this article as:
| Copy the following to cite this article: Asadi-Ghalehni M, Rasaee M. J, Javanmardi M, Khalili S, Mohamadi M, Fatemi F, Sadroddiny E. in Silico and in Vitro Evaluation of A Recombinant Fusion Peptide as A Novel Candidate Vaccine for EGFR-Positive Tumors. Biosci Biotechnol Res Asia 2015;12(3) |
| Copy the following to cite this URL: Asadi-Ghalehni M, Rasaee M. J, Javanmardi M, Khalili S, Mohamadi M, Fatemi F, Sadroddiny E. in Silico and in Vitro Evaluation of A Recombinant Fusion Peptide as A Novel Candidate Vaccine for EGFR-Positive Tumors. Biosci Biotechnol Res Asia 2015;12(3). Available from: https://www.biotech-asia.org/?p=4130 |
share this article
Follow us on:
Member of
Journal archived in
